This website uses cookies. By continuing you are agreeing to our privacy policy.

Piro Lito, M.D., Ph.D.

Headshot of Piro Lito, M.D., Ph.D.
Memorial Sloan-Kettering Cancer Center
Treating Lung Cancer With KRAS Mutation

Approximately 25 percent of patients with lung cancer harbor mutations in a cancer-causing protein called KRAS. This is the most frequently activated protein found in cancer patients. While precision medicines--which target proteins that are activated less frequently--have revolutionized the care of patients with lung cancer, no such medicines are available to treat patients whose tumors harbor a KRAS mutation. Recent advances have led to the discovery of drugs that target a particular KRAS mutation, KRAS G12C, which is the most common KRAS mutation in patients with lung cancer. Building on our work describing the mechanism of action of these drugs, we will investigate how cancer cells bypass inhibition of KRAS and then identify optimal combination therapies, in order to maximize the effect of these drugs in patients.

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.